Table 1.

Reasons for receiving alloHCT after targeted therapies

	n (%)
del(17p)*	22 (76)
No. of prior therapies ≥3	22 (73)
Complex karyotype (≥5 abnormalities)*	12 (46)
IGHV unmutated*	15 (79)
Refractory to or relapsed after FCR prior to targeted therapy	4 (13)
Poor response to conventional chemotherapy	2 (7)
Poor response to targeted therapy	3 (10)
Richter transformation	3 (10)

FCR, fludarabine, cyclophosphamide, and rituximab.

^*Missing data are excluded from the denominator in calculation of percentage. The denominator is 29, 26, and 19 for del(17p), complex karyotype, and IGHV unmutated, respectively.